Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

N Engl J Med. 2024 Oct 10;391(14):1364. doi: 10.1056/NEJMc2410841.

Marko Lucijanic ¹, Anica Sabljic ¹, Ivan Krecak ²

Affiliations

Affiliations

1 Dubrava University Hospital, Zagreb, Croatia [email protected].
2 University of Rijeka Faculty of Medicine, Rijeka, Croatia.

PMID: 39383465 DOI: 10.1056/NEJMc2410841

Products

Cat. No.

Product Name

Description

Target

Research Area
HY-P9980

Belantamab

99.90%, Anti-BCMA/TNFRSF17 Monoclonal Antibody

ADC Antibody; TNF Receptor

Cancer

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator; DNA/RNA sequence conversion tools

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2026 MedChemExpress. All Rights Reserved.: Site Map Privacy and Cookie Policy

Join with us